aspiration case report semaglutide anesthesia 2023 Perioperative management of GLP-1 receptor agonists: a systematic review of potential risks | Perioperative Medicine Canadian Journal of Anesthesia/Journal canadien

The foundation remains real food, good habits

Lets continue the discussion below

GLP-1 receptor agonists (GLP-1s) have recently become high-profile drugs for type 2 diabetes (T2D) and especially for obesity/weight loss

Resistance training sends a biological signal to your body that muscle mass is currently necessary and should be retained rather than metabolized for energy

Methods Data sources and search strategy This systematic review was conducted up to 01 December 2024 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines

Across its client base, Virta has: Discontinued GLP-1 use in over 50% of active users Kept GLP-1 utilization under 25% across all weight loss members Achieved about 5% average weight loss in 90 days, with durable outcomes post-medication Optional outcomes-based contracts available for employers seeking risk alignment Omada Health supports chronic disease and weight management through connected devices, digital coaching, and virtual care teams